Subject(s)
Adenocarcinoma , Stomach Neoplasms , Humans , Male , Middle Aged , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/pathology , Color , Gastric Fundus/diagnostic imaging , Gastric Fundus/pathology , Image Enhancement/methods , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/pathologyABSTRACT
OBJECTIVES: The aim of this study was to evaluate the applicability of genotyping of the ABCG2 gene using MALDI-TOF MS and to estimate the allele frequency in the Japanese population. BACKGROUND: Jr (a-) phenotype has a prevalence of approximately 0·05% among Japanese blood donors; DNA-based genotyping was conducted to investigate the molecular basis of the Jr (a-) phenotype along with serological typing. To detect all SNPs of the ABCG2 gene, a high-throughput SNP genotyping platform is needed. METHODS: Overall, 1004 Jr (a-) blood samples were collected from blood donors in Japan and pre-genotyped. To detect the SNPs of the ABCG2 gene using MALDI-TOF MS, polymerase chain reaction and unextend primer were designed. In total, 205 Jr (a-) samples were genotyped using MALDI-TOF MS analysis. RESULTS: The SNPs of 1004 Jr (a-) samples were identified using the HRM analysis and DNA sequencing, and 799 of 1004 (80%) Jr (a-) samples had the homozygous for c.376 T. The designed primers for MALDI-TOF MS perfectly detected the SNPs of the ABCG2 gene. A total of 205 Jr (a-) samples were genotyped using MALDI-TOF MS. Calling failures occurred in only two samples with the mutations c.736CT to c.376C and c.421C to c.421CA. The concordance rate between the pre-genotyped and MALDI-TOF MS-based genotyping results was very high (99·02%) for all ABCG2 alleles. CONCLUSIONS: Jr (a-) Japanese donors had almost the homozygous for c.376 T. However, detections of more than 20 SNPs of the ABCG2 gene for the JR blood group genotyping are needed. MALDI-TOF MS-based genotyping was highly concordant with the pre-genotyped results for all ABCG2 alleles.
Subject(s)
ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics , Genotyping Techniques/methods , Neoplasm Proteins/genetics , Polymorphism, Single Nucleotide , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Asian People , Female , Genotyping Techniques/instrumentation , Humans , Japan , MaleABSTRACT
We study the angular broadening of a medium-induced QCD cascade. We derive the equation that governs the evolution of the average transverse momentum squared of the gluons in the cascade as a function of the medium length, and we solve this equation analytically. Two regimes are identified. For a medium of a not too large size, and for not too soft gluons, the transverse momentum grows with the size of the medium according to standard momentum broadening. The other regime, visible for a medium of a sufficiently large size and very soft gluons, is a regime dominated by multiple branchings: there, the average transverse momentum saturates to a value that is independent of the size of the medium. This structure of the in-medium QCD cascade is, at least qualitatively, compatible with the recent LHC data on dijet asymmetry.
ABSTRACT
BACKGROUND AND OBJECTIVES: At Japanese Red Cross (JRC) Blood Centers, all donated blood is screened for hepatitis C virus (HCV) by serological and nucleic acid amplification testing. Donor plasma that tested reactive for anti-HCV by serological test is disqualified even if the donor tests negative for HCV RNA. These test results reflect both true-positive results because of past HCV infection and false-positive results because the cross-reactivity of plasma IgG, which current testing methods are unable to distinguish. To characterize these antibody test results, we examined the neutralizing activity of these plasma samples. MATERIAL AND METHODS: Donor plasma samples that tested reactive for anti-HCV by serological test but negative for HCV RNA (n = 43) were analysed for determining their neutralizing activities measured by the inhibition of the cellular entry of pseudoparticles harbouring HCV envelope glycoproteins (HCVpp). RESULTS: Strong and broad neutralizing activities against HCVpp entry similar to the samples that tested reactive for anti-HCV serological test and positive for HCV RNA (considered to be derived from individuals with chronic HCV infection) were observed in three of 43 plasma samples from donors who tested anti-HCV reactive but HCV RNA negative. CONCLUSION: By examining the neutralizing activities of plasma samples, we identified individuals with a past HCV infection from those in whom we were unable to confirm HCV infection according to the current testing algorithms of JRC, which do not perform anti-HCV confirmatory tests.
Subject(s)
Antibodies, Viral/blood , Blood Donors , Hepacivirus/immunology , Neutralization Tests/methods , Cell Line, Tumor , HEK293 Cells , Hepacivirus/genetics , Humans , Nucleic Acid Amplification Techniques , RNA, Viral/blood , RNA, Viral/geneticsABSTRACT
BACKGROUND AND OBJECTIVES: We developed a hollow-fibre column system specifically adapted to prepare washed platelet concentrates (WPCs). This study was performed to evaluate the efficacy of the hollow-fibre column system for preparing WPCs. MATERIALS AND METHODS: First, the percentages of platelet (PLT) recovery and remaining plasma proteins were calculated by determining the PLT count, volume and plasma protein levels in both the prewash and postwash. Secondly, washed PLTs and unwashed control PLTs were stored for 5 days, and the changes during this 5-day storage of in vitro PLT characteristics were determined. RESULTS: The hollow-fibre column system effectively removed >98% of plasma in platelet concentrates (PCs), and the PLT recovery was 97% on an average. The CD62P-expression level on washed PLTs immediately after washing was approximately twofold higher than that on prewashed PLTs as well as on PLTs washed via manual methods or cell washing devices. Until day 5 during storage, PLT aggregability, hypotonic shock response and swirling scores of washed PLTs were not significantly different from those of the control PCs. CONCLUSION: Our novel hollow-fibre column system proved valuable in preparing washed PLTs with <2% of residual plasma proteins and high recovery of PLTs.
Subject(s)
Blood Platelets/cytology , Blood Preservation/methods , Blood Platelets/metabolism , Blood Preservation/instrumentation , Glucose/metabolism , Humans , Lactic Acid/metabolism , Time FactorsABSTRACT
The International Society of Blood Transfusion Working Party on red cell immunogenetics and blood group terminology convened during the International congress in Cancun, July 2012. This report details the newly identified antigens in existing blood group systems and presents three new blood group systems.
Subject(s)
Blood Group Antigens/classification , Terminology as Topic , Blood Group Antigens/genetics , Blood Group Antigens/immunology , Humans , Immunogenetics , Societies, ScientificABSTRACT
BACKGROUND: Blood-group genotyping arrays have been widely used in Caucasian and African American populations, but have not been thoroughly tested in Japanese subjects. AIM: To evaluate, using the BLOODchip(®) Reference genotyping system, the concordance of previously typed samples with expected phenotypes and the coverage of the Japanese variants. METHODS: Blood samples from 100 Japanese donors were obtained. DNA was extracted with QIAsymphony (Qiagen, Hilden, Germany). Samples were typed by serological methods and processed with the BLOODchip(®) . When a non-concordant result was identified, further sequencing by polymerase chain reaction-single specific primer (PCR-SSP) was performed. RESULTS: Concordance between systems was 98% (736/751), and 98.8% (742/751) if only non-software-related non-concordances were considered. In the ABO group, 6 'No Call' (NC, inability of the BLOODchip(®) to assign a result) were ascribed to a variant of blood subtype A1 (A102; 467C>T), a common subtype in Asian populations, whereas three NC presented additional polymorphisms not contained in the BLOODchip(®) (A102/A205, A102/O06 and A204/O02). In the RhD group, one discrepancy was correctly genotyped as RHD*1227A (Del phenotype) by the BLOODchip(®) (phenotyped as partial D, RHD*DIVb). Another was phenotyped as D+ by the BLOODchip(®) (phenotyped weak D by serology) and confirmed as RHD*D-CE(2)-D heterozygous by sequencing. The 3 RhD NC can be solved by further software update. For RhCE, one discrepancy was correctly genotyped for both systems; however, only the BLOODchip(®) was able to detect RHCE*CX allele. CONCLUSIONS: By programming the A102 ABO variant into the system software with the new allele combinations, the BLOODchip(®) Reference is a suitable genotyping tool to be applied to Asian samples.
Subject(s)
Blood Group Antigens/genetics , Blood Grouping and Crossmatching , Genotyping Techniques , Adult , Asian People , Blood Group Antigens/blood , Blood Grouping and Crossmatching/instrumentation , Blood Grouping and Crossmatching/methods , Female , Genotyping Techniques/instrumentation , Genotyping Techniques/methods , Humans , Infant, Newborn , Japan , Male , Sensitivity and SpecificityABSTRACT
We study the average properties of the gluon cascade generated by an energetic parton propagating through a quark-gluon plasma. We focus on the soft, medium-induced emissions which control the energy transport at large angles with respect to the leading parton. We show that the effect of multiple branchings is important. In contrast with what happens in a usual QCD cascade in vacuum, medium-induced branchings are quasidemocratic, with offspring gluons carrying sizable fractions of the energy of their parent gluon. This results in an efficient mechanism for the transport of energy toward the medium, which is akin to wave turbulence with a scaling spectrum ~1/sqrt[ω]. We argue that the turbulent flow may be responsible for the excess energy carried by very soft quanta, as revealed by the analysis of the dijet asymmetry observed in Pb-Pb collisions at the LHC.
ABSTRACT
AIMS: Skin autofluorescence, a non-invasive measure of the accumulation for advanced glycation end products, has been reported to be a useful marker for diabetic vascular risks in the Caucasian population. The aim of this study was to evaluate associations between skin autofluorescence and vascular complications in non-Caucasian patients with Type 2 diabetes. METHODS: Subjects in this cross-sectional study comprised 130 Japanese patients with Type 2 diabetes. Skin advanced glycation end products were assessed by skin autofluorescence using an autofluorescence reader. Association between skin autofluorescence and severity of vascular complications was evaluated. RESULTS: Of the 130 patients, 60 (46.2%) had microvascular complications such as diabetic retinopathy, neuropathy and nephropathy, 10 (7.7%) had macrovascular complications and 63 (48.5%) had micro- and/or macrovascular complications. Skin autofluorescence increased with severity of vascular complications. Independent determinants of skin autofluorescence were age (ß = 0.24, P < 0.01), mean HbA(1c) in previous year (ß = 0.17, P = 0.03), microvascular complications (ß = 0.44, P < 0.01) and macrovascular complications (ß = 0.27, P < 0.01). Multiple logistic regression analysis revealed that diabetes duration (odds ratio 1.15, P < 0.01), systolic blood pressure (odds ratio 1.04, P = 0.01), skin autofluorescence (odds ratio 3.62, P = 0.01) and serum albumin (odds ratio 0.84, P < 0.01) were independent factors for the presence of vascular complications in these patients. CONCLUSIONS: Skin autofluorescence had independent effects on vascular complications in Japanese patients with Type 2 diabetes. This indicates that skin advanced glycation end products are a surrogate marker for vascular risk and a non-invasive autofluorescence reader may be a useful tool to detect high-risk cases in non-Caucasian patients with diabetes.
Subject(s)
Cardiovascular Diseases/etiology , Diabetes Mellitus, Type 2/complications , Fluorescence , Glycation End Products, Advanced/metabolism , Skin/metabolism , Smoking/adverse effects , Aged , Asian People , Blood Pressure , Body Mass Index , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/metabolism , Cross-Sectional Studies , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/metabolism , Diabetic Angiopathies/epidemiology , Diabetic Angiopathies/etiology , Diabetic Angiopathies/metabolism , Diabetic Nephropathies/epidemiology , Diabetic Nephropathies/etiology , Diabetic Nephropathies/metabolism , Diabetic Neuropathies/epidemiology , Diabetic Neuropathies/etiology , Diabetic Neuropathies/metabolism , Diabetic Retinopathy/epidemiology , Diabetic Retinopathy/etiology , Diabetic Retinopathy/metabolism , Female , Glycated Hemoglobin/metabolism , Humans , Male , Middle Aged , Reproducibility of Results , Risk FactorsABSTRACT
BACKGROUND: The Japanese Red Cross (JRC) conducted a prospective study to evaluate the frequency of transfusion-transmitted HBV, HCV and HIV infections to assess the risk of transfusion of blood components routinely supplied to hospitals. STUDY DESIGN AND METHODS: Post-transfusion specimens from patients at eight medical institutes were examined for evidence of infection with HBV (2139 cases), HCV (2091) and HIV (2040) using individual nucleic acid amplification testing (NAT). If these specimens were reactive, pre-transfusion specimens were also examined for the virus concerned by individual NAT. In the event that the pre-transfusion specimen was non-reactive, then all repository specimens from implicated donors were tested for the viruses by individual donation NAT. In addition, a further study was carried out to evaluate the risk of transfusion of components from donors with low anti-HBc titres or high anti-HBc with high anti-HBs titres. RESULTS: Transfusion-transmitted HCV and HIV infections were not observed. One case of post-transfusion HBV infection was identified (rate, 0·0004675; 95% CI for the risk of transmission, 1 in 451-41,841). The background rates of HBV, HCV and HIV infections in patients prior to transfusion were 3·4% (72/2139), 7·2% (150/2091) and 0% (0/2040), respectively. Sixty-four anti-HBc- and/or anti-HBs-reactive blood components were transfused to 52 patients non-reactive for anti-HBc or anti-HBs before and after transfusion (rate, 0; 95% CI for the risk of transmission, <1 in 22). CONCLUSION: This study demonstrated that the current criteria employed by JRC have a low risk, but the background rates of HBV and HCV infections in Japanese patients are significant.
Subject(s)
Blood Donors , Hepatitis B , Hepatitis C , Transfusion Reaction , Virus Diseases/transmission , HIV Infections/transmission , Hepatitis B/transmission , Hepatitis B Antibodies/blood , Hepatitis C/transmission , Humans , Prospective Studies , RiskABSTRACT
We analyzed the stimulatory effect of oncostatin M (OSM), leukemia inhibitory factor (LIF), interleukin 6 (IL-6), IL-11, and the inhibitory effect of anti-IL-6 antibody (Ab), anti-IL-6 receptor monoclonal antibody (mAb), and anti-gp130 mAb on the growth of human plasmacytoma cells freshly isolated from a patient with multiple myeloma. The purified cells showed a plasmacytoid morphology and expressed CD38, CD54, and CD56 antigens but no CD3, CD5, CD10, CD19, CD20, or very late antigen 5. IL-6 receptor (IL-6R) and its signal transducer, gp130, were expressed on their cell surface at a low level. Dose-dependent proliferation of the cells in response to OSM, LIF, and IL-6, but not to IL-11, was observed using [3H]TdR incorporation in vitro. Both anti-IL-6 Ab and anti-IL-6R mAb inhibited the growth of the cells in the presence or absence of exogenous IL-6. These cells release IL-6 but not OSM or LIF into the culture supernatant during short-term culture. Therefore, an autocrine growth mechanism mediated by IL-6, but not by OSM or LIF, was confirmed. Furthermore, anti-gp130 mAb completely inhibited the proliferation of the cells induced by OSM, LIF, as well as IL-6. These data indicate that OSM, LIF, and IL-6 can act as growth factors of human plasmacytoma cells through a common signal transducer, gp130, on their cell surface, and also suggest the potential therapeutic application of anti-gp130 mAb, as well as anti-IL-6R mAb against myeloma/plasmacytomas.
Subject(s)
Antigens, CD , Growth Inhibitors/physiology , Interleukin-6/physiology , Lymphokines/physiology , Membrane Glycoproteins/physiology , Peptides/physiology , Plasmacytoma/pathology , Signal Transduction , Antibodies, Monoclonal , Bone Neoplasms/pathology , Cell Division , Cytokine Receptor gp130 , Humans , Interleukin-11/physiology , Interleukin-6/immunology , Leukemia Inhibitory Factor , Male , Middle Aged , Multiple Myeloma/pathology , Oncostatin M , Plasmacytoma/immunology , Tumor Cells, CulturedABSTRACT
AT11-2, an Abelson virus-transformed cell line has DJH complexes on both chromosomes and is able to form functional variable region genes by the joins of VH genes to the DJH complexes during culture. Therefore we examined which VH gene family was used in functional VH to DJH recombinations in AT11-2. Surprisingly, of 32 independent functional VH to DJH recombinational events in AT11-2, 31 events used the VH segments of the VHQ52 family, and the remaining one used the VH segment of the VH7183 family. Thus, we describe here the first B precursor cell line that almost selectively uses the VHQ52 family in functional VH to DJH rearrangements. The selective use of the VHQ52 family in this B precursor cell line strongly indicates nonrandom use of VH gene families, and the existence of a stage at which the VHQ52 family is preferentially used during the normal development of early pre-B cells and has important implications for understanding the ontogeny of VH repertoire development. Furthermore, this cell line should prove extremely valuable in further studies of this kind.
Subject(s)
B-Lymphocytes/immunology , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , Animals , Cell Line , Cell Transformation, Viral , Mice , Mice, Inbred BALB C , Recombination, GeneticABSTRACT
Ectopic ACTH-producing tumors preferentially secrete biologically inactive ACTH precursors and ACTH-related fragments. DMS-79 is known to secrete unprocessed high-molecular-weight (HMW) form ACTH. To determine whether prohormone convertase (PC) 1/3 is involved in the abnormal processing of proopiomelanocortin (POMC), we studied whether PC1/3 and 2 genes are expressed in DMS-79, and whether overexpression of PC1/3 gene affects POMC processing pattern. Steady-state mRNA levels of PC1/3 and 2 were determined by real-time RT-PCR. Molecular weights of ACTH-related peptides were determined by chromatographical analyses coupled with ACTH and beta-endorphin (beta-END) radioimmunoassays. PC1/3 gene was transfected into DMS-79 by retrovirus transduction using pMX-IP vector encoding PC1/3 cDNA. The steady-state mRNA levels of PC1/3 and 2 in DMS-79 were lower than those in ACTH-secreting and nonfunctioning pituitary tumors. DMS-79 predominantly secreted HMW form with both ACTH and beta-END immunoreactivities by size-exclusion chromatography. After purification by immunoaffinity chromatography with anti-ACTH antibody, the apparent molecular weight of HMW form ACTH was estimated to be 16 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with silver staining. After retroviral transfection of PC1/3 cDNA into DMS-79 and puromycin selection, PC1/3 stably-expressing cell line (DMS-79T) secreted two immunoreactive ACTH components, a major one coeluting with ACTH(1-39) and a minor one as a HMW form as well as two beta- END immunoreactive components coeluting with beta-lipotropic hormone and beta-END, respectively. Thus, we have established PC1/3 stably-expressing cell line (DMS-79T) capable of proteolytically processing ACTH precursor molecule(s) into mature ACTH and beta-END.
Subject(s)
Adrenocorticotropic Hormone/biosynthesis , Adrenocorticotropic Hormone/metabolism , Gene Expression , Pro-Opiomelanocortin/metabolism , Proprotein Convertase 1/genetics , Adenoma/metabolism , Cell Line, Tumor , Electrophoresis, Polyacrylamide Gel , Humans , Lung Neoplasms , Molecular Weight , Pituitary Neoplasms/metabolism , Proprotein Convertase 1/metabolism , Proprotein Convertase 2/genetics , Proprotein Convertase 2/metabolism , RNA, Messenger/analysis , Retroviridae/genetics , Small Cell Lung Carcinoma , Transfection , beta-Endorphin/metabolismABSTRACT
Protein tyrosine phosphorylation is a common mechanism of signaling in pathways that regulate T cell receptor-mediated cell activation, cell proliferation, and the cell cycle. Because human immunodeficiency virus (HIV) is though to affect normal cell signaling, tyrosine phosphorylation may be associated with HIV cytopathicity. In both HIV-infected cells and transfected cells that stably express HIV envelope glycoproteins undergoing HIVgp41-induced cell fusion, a 30-kilodalton protein was phosphorylated on tyrosine with kinetics similar to those of syncytium formation and cell death. When tyrosine phosphorylation was inhibited by the protein tyrosine kinase inhibitor herbimycin A, envelope-mediated syncytium formation was coordinately reduced. These studies show that specific intracellular signals, which apparently participate in cytopathicity, are generated by HIV and suggest strategies by which the fusion process might be interrupted.
Subject(s)
Cytopathogenic Effect, Viral/physiology , HIV-1/physiology , Phosphoproteins/metabolism , Signal Transduction/physiology , T-Lymphocytes/physiology , Tyrosine/metabolism , Benzoquinones , CD4 Antigens/physiology , Cell Line , HIV Envelope Protein gp41/genetics , HIV Envelope Protein gp41/physiology , Humans , Lactams, Macrocyclic , Phosphorylation , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/metabolism , Quinones/pharmacology , Receptors, Antigen, T-Cell/physiology , Rifabutin/analogs & derivatives , T-Lymphocytes/microbiology , Transfection , Viral Envelope Proteins/genetics , Viral Envelope Proteins/physiologyABSTRACT
Our goal in the present study was to evaluate antitumor effects and frequency of tumor-infiltrating immune cells upon intratumoral injection of RGD fiber-mutant adenoviral vector (AdRGD) encoding the chemokines CCL17, CCL19, CCL20, CCL21, CCL22, CCL27, XCL1, and CX3CL1. Among eight kinds of chemokine-expressing AdRGDs, AdRGD-CCL19 injection most efficiently induced infiltration of T cells into established B16BL6 tumor parenchyma, whereas most of these T cells were perforin-negative in immunohistochemical analysis. Additionally, the growth of AdRGD-CCL19-injected tumors decreased only slightly as well as that of other tumors treated with each chemokine-expressing AdRGD, which indicated that accumulation of naive T cells in tumor tissue does not effectively damage the tumor cells. Tumor-bearing mice, in which B16BL6-specific T cells were elicited by dendritic cell-based immunization, demonstrated that intratumoral injection of AdRGD-CCL17, -CCL22, or -CCL27 could considerably suppress tumor growth and attract activated T cells. On the other hand, AdRGD-CCL19-injection in the immunized mice showed slight increase of tumor-infiltrating T cells compared to treatment using control vector. Collectively, although AdRGD-mediated chemokine gene transduction into established tumors would be very useful for augmentation of tumor-infiltrating immune cells, a combinational treatment that can systemically induce tumor-specific effector T cells is necessary for satisfactory antitumor efficacy.
Subject(s)
Adenoviridae/genetics , Chemokines/biosynthesis , Genetic Vectors , Lymphocyte Subsets/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma, Experimental/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Capsid Proteins/genetics , Cell Line, Tumor , Chemokines/genetics , Chemokines/immunology , Dendritic Cells/immunology , Female , Genetic Therapy , Genetic Vectors/immunology , Melanoma, Experimental/pathology , Melanoma, Experimental/therapy , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Mice , Mice, Inbred C57BL , Mutation , Oligopeptides/genetics , Transduction, Genetic , gp100 Melanoma AntigenABSTRACT
cDNAs for alpha 1,4 galactosyltransferase (A4GALT) have been isolated. To explore the molecular basis of the p phenotype in Japanese donors, we analyzed the A4GALT gene sequences of normal and p phenotype samples. The coding region in the A4GALT gene for DNA sequencing was amplified by PCR amplification. A4GALT expression vectors for individual were constructed by PCR amplification of the coding region using primers and subsequent subcloning into an expression vector. The expression of Gb3/CD77 antigen on the cell surface was evaluated by flow cytometry and by immunochemical techniques. All individuals with the p phenotype were found to have a single base insertion (A4GALT/insC) at the same nucleotide position. Neither the transfectant cells with a mutant gene (A4GALT/insC) of donor origin or those with a synthesized mutant gene (A4GALT/insC-Mu) expressed Gb3 antigen indicating that the presence of A4GALT/insC diminished the A4GALT enzyme activity. In addition, an allele-specific PCR (ASP) system was developed in which of the p phenotype with A4GALT/insC can be unambiguously discriminated from normal donors. Based on the finding that a single base insertion (A4GALT/insC) diminishes A4GALT activity, an ASP assay was developed to detect individuals with this particular p phenotype.
Subject(s)
Antigens, Tumor-Associated, Carbohydrate/biosynthesis , Galactosyltransferases/genetics , Gene Expression Regulation, Enzymologic/genetics , Mutagenesis, Insertional , P Blood-Group System/biosynthesis , Antigens, Tumor-Associated, Carbohydrate/genetics , Cell Line , Frameshift Mutation , Galactosyltransferases/analysis , Galactosyltransferases/biosynthesis , Humans , Mutagenesis, Insertional/methods , P Blood-Group System/genetics , Polymerase Chain Reaction/methods , Transfection/methodsABSTRACT
The Working Party has met twice since the last report: in Seoul, South Korea 2014, and in London, UK 2015, both in association with the International Society of Blood Transfusion (ISBT) Congress. As in previous meetings, matters pertaining to blood group antigen nomenclature were discussed. Eleven new blood group antigens were added to seven blood group systems. This brings the current total of blood group antigens recognized by the ISBT to 346, of which 308 are clustered within 36 blood groups systems. The remaining 38 antigens are currently unassigned to a known blood group system.